Lupin Ltd

Lupin Employee Stock Options

Lupin Ltd allotted 24,111 equity shares to employees following the exercise of vested stock options under the company's ESOP schemes.

Lupin Product Launch

Lupin received US FDA approval for Modafinil Tablets, USP, a generic version of Provigil. This regulatory approval enables the company to market the drug in the U.S.

Lupin Employee Stock Options

Lupin Limited allotted 30,967 equity shares under its Employee Stock Option Plan. This allotment increases the company's total issued and paid-up equity share capital.

Lupin Other Announcement

Lupin Limited received an ESG rating of '60' ('Adequate' category) from ESG Risk Assessments & Insights Limited, which was assigned independently without company engagement.

Lupin Partnership

Lupin Limited's subsidiary VISUfarma B.V. signed an exclusive license agreement with Visus Therapeutics to commercialize YUVEZZI™ in Europe. The deal includes potential consideration of €75 million.

Value

₹832.5 Cr

Execution

Initial term until 20th anniversary of first commercial sale

Lupin Management Change

Lupin Limited announced the sad demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, on August 17, 2026.

Lupin Regulatory Approval

Lupin received U.S. FDA approval for Sodium Zirconium Cyclosilicate for Oral Suspension. The drug treats hyperkalemia in adults.

Lupin Earnings Call Transcript: Key Takeaways

Lupin reported record Q1 FY27 revenues of ₹8,277 crore with strong EBITDA margins of 30%. Growth was broad-based across US and India, though management expects near-term US moderation due to increased competition in key products.

Lupin Investor Presentation: Key Takeaways

Lupin delivered strong Q1 FY27 results with 33% YoY revenue growth and healthy 30% EBITDA margins, driven by outperformance in US and India markets.

Lupin Q1 FY27 Results: Net Profit ₹1,415 Cr, Up 16.1% YoY

Lupin Ltd reported revenue from operations of ₹8,277 Cr (+32.0% YoY) and net profit of ₹1,415 Cr (+16.1% YoY) for Q1 FY27.

Key figure

Net profit ₹1,415 Cr · +16.1% YoY

Lupin Q1 FY27 Results: Net Profit ₹1,417 Cr, Up 16.0% YoY

Lupin Ltd reported revenue from operations of ₹8,277 Cr (+32.0% YoY) and net profit of ₹1,417 Cr (+16.0% YoY) for Q1 FY27.

Key figure

Net profit ₹1,417 Cr · +16.0% YoY

Lupin Annual General Meeting

Lupin Limited held its 44th Annual General Meeting on August 04, 2026. All proposed resolutions, including dividend declaration, were passed with the requisite majority.

Lupin Business Update

Lupin received US FDA approval for its Diazepam Injection, USP, enabling its commercialization in the U.S. market.

Lupin Product Launch

Lupin Limited has launched Sugammadex Injection in the United States following U.S. FDA approval. The product is a bioequivalent to Merck's Bridion® for reversing neuromuscular blockade.

Lupin Board Meeting Date

Lupin Limited has scheduled a Board Meeting for August 06, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.

Lupin Merger & Restructuring Worth ₹15.36 Cr

Lupin Inc. licensed two oncology programs to Kaveri Therapeutics in exchange for an 82.2% stake, valued at ₹15.36 Crore.

Value

₹15.36 Cr

Lupin Other Announcement

Lupin Ltd has submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended June 30, 2026. This disclosure details the current equity distribution structure.

Lupin Annual General Meeting

Lupin Limited scheduled its 44th AGM for August 4, 2026. Key agenda items include adopting financial statements, declaring dividends, and appointing Deloitte Haskins & Sells as statutory auditors.

Value

₹0.10 Cr

Lupin Business Update

Lupin Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's environmental, social, and governance performance.

Lupin Annual General Meeting

Lupin Limited will hold its 44th AGM on August 4, 2026. The record date for the final dividend of ₹18 per share is July 17, 2026.

Lupin Employee Stock Options

Lupin Ltd allotted 2,358 shares under ESOP. This increases its paid-up capital to ₹91.44 Crore.

Lupin Business Update

Lupin received an EIR from the U.S. FDA for its Somerset facility. The inspection resulted in a satisfactory VAI classification.

Lupin Merger & Restructuring

Lupin's subsidiary Nanomi completed the acquisition of shares in MPPI. This increases Nanomi's effective shareholding in MPPI to 99.89%.

Lupin Employee Stock Options

Lupin Limited approved granting 65,251 stock options under its 2025 scheme. Options vest over three years subject to performance conditions.

Execution

three years

Lupin Regulatory Approval

Lupin received tentative U.S. FDA approval for Enzalutamide Tablets. The approval covers strengths of 40mg, 80mg, 120mg, and 160mg.

Lupin Partnership

Lupin collaborated with Laboratorios ERN S.A. to launch its Luforbec inhaler in Spain. This strategic partnership expands Lupin's respiratory market footprint into the Spanish therapeutic sector.

Lupin Regulatory Approval

Lupin received U.S. FDA approval for Ranluspec, an interchangeable biosimilar for Lucentis. This milestone expands the company's ophthalmology portfolio in the American market.

Lupin Employee Stock Options

Lupin Limited allotted 16,673 equity shares following the exercise of vested employee stock options. This increases the company's total paid-up share capital to 45,72,32,536 shares.

Lupin Regulatory Approval

Lupin and Natco received U.S. FDA approval for Eribulin Mesylate Injection. The reference drug has estimated annual U.S. sales of ₹415.15 Crore.

Value

₹415.1 Cr

Lupin Regulatory Approval

Lupin received U.S. FDA approval for its Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride tablets. The product targets a USD 132.8 million market.

Value

₹1,262 Cr

Execution

180-day generic drug exclusivity